Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of EMPAGLINAZ - M 12.5/1000 vs JARDIANCE DUO 12.5 mg/1000 mg under fed conditions in healthy Thai adults
TCTR20241215014Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of empagliflozin (2 arms), sponsored by Bio-innova. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
empagliflozin
Beyond the preview
Go deeper on TCTR20241215014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241215014.